Click here for details and downloads (registration is not required)URL: www.nec.com/en/global/solutions/ai-drug/publication/index.html
NEC is committed to taking on the challenge of realizing new cancer treatments by aiming to establish an accurate, reliable, and comprehensive process workflow that utilizes AI and security technologies.
In recent years, there have been growing expectations for personalized neoantigen cancer vaccines as a next-generation cancer therapy. Personalized neoantigen cancer vaccines are a type of cancer immunotherapy that targets neoantigens containing genomic mutations that are specific to each patient. NEC is working on the realization of personalized cancer vaccines by using one of its core technologies, AI, to identify target neoantigens from each individual patient's genome data.
This white paper proposes a comprehensive process workflow for personalized cancer vaccines, from design to administration, and the perspectives that should be discussed in this flow. Furthermore, NEC's advanced ICT technologies are introduced to address these perspectives, and the possibility that the use of ICT technology will contribute to the realization of a platform for not only personalized cancer vaccines, but also for various cancer treatments are discussed.
About
Copyright 2024 JCN Newswire . All rights reserved.
© Japan Corporate News, source